According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

The launch of Journavx represents Vertex’s entry into the pain management market, a move that could significantly diversify its revenue streams. The non-opioid nature of Journavx is expected to ...

Vertex has established itself as a dominant player in the CF market, with a portfolio of transformative medicines that have significantly improved patient outcomes. The company’s recent approval of ...

Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...

The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a ...

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...

Vertex has been a phenomenal growth stock, and with the FDA approval of its non-opioid pain medication Journavx in January, more growth could be on the way. The company's highly profitable ...

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...

Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...